IL1B and atherosclerosis: Antibodies against IL-1β (canakinumab, gevokizumab, LY2189) and IL-1 receptor antagonists (anakinra) represent potential therapeutics for T2DM and atherosclerosis and have already been tested successfully in human studies [85,181,249,250,251,252,253].